Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 112-86-7 | MDL No. : | MFCD00063188 |
Formula : | C22H42O2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | DPUOLQHDNGRHBS-KTKRTIGZSA-N |
M.W : | 338.57 | Pubchem ID : | 5281116 |
Synonyms : |
Docosenoic acid (cis-13);cis-13-docosenoic acid;C22:1(cis-13)Fatty acid
|
Chemical Name : | (Z)-Docos-13-enoic acid |
Num. heavy atoms : | 24 |
Num. arom. heavy atoms : | 0 |
Fraction Csp3 : | 0.86 |
Num. rotatable bonds : | 19 |
Num. H-bond acceptors : | 2.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 109.17 |
TPSA : | 37.3 Ų |
GI absorption : | Low |
BBB permeant : | No |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -1.4 cm/s |
Log Po/w (iLOGP) : | 5.22 |
Log Po/w (XLOGP3) : | 9.81 |
Log Po/w (WLOGP) : | 7.67 |
Log Po/w (MLOGP) : | 5.47 |
Log Po/w (SILICOS-IT) : | 7.71 |
Consensus Log Po/w : | 7.17 |
Lipinski : | 1.0 |
Ghose : | None |
Veber : | 1.0 |
Egan : | 1.0 |
Muegge : | 2.0 |
Bioavailability Score : | 0.56 |
Log S (ESOL) : | -6.87 |
Solubility : | 0.0000462 mg/ml ; 0.000000136 mol/l |
Class : | Poorly soluble |
Log S (Ali) : | -10.51 |
Solubility : | 0.0000000104 mg/ml ; 0.0 mol/l |
Class : | Insoluble |
Log S (SILICOS-IT) : | -6.99 |
Solubility : | 0.000035 mg/ml ; 0.000000104 mol/l |
Class : | Poorly soluble |
PAINS : | 0.0 alert |
Brenk : | 1.0 alert |
Leadlikeness : | 2.0 |
Synthetic accessibility : | 3.53 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
30.2% | With di-tert-butyl peroxide; C52H80CoN2O10; oxygen; In tetrahydrofuran; at 140℃; under 5250.53 Torr; for 5h;Autoclave; | 3.4 g (0.01 mol) of erucic acid and 0.095 g (0.0001 mol) were added to the autoclave.a cobalt complex of an isosteric alcohol derivative, 34.0 g of tetrahydrofuran,1.6 g (0.012 mol) of t-butanol peroxide,Passing oxygen to the reactor pressure of 0.7 MPa, the reaction temperature is 140 C,The reaction time is 300 minutes. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With oxalyl dichloride; N,N-dimethyl-formamide; In dichloromethane; at 0℃; for 3h;Inert atmosphere; | To a stirred solution of fatty acid in dichloromethane (DCM), catalytic amount of dimethyl formamide (DMF) was added and the contents were stirred at 0 C. Oxalyl chloride was added under nitrogen atmosphere and the reaction mixture was further stirred at 0 C for 3 h. Then reaction mixture was concentrated under reduced pressure to remove DCM and excess oxalyl chloride. Later crude acid chloride dissolved in DCM was used for the next step directly under nitrogen atmosphere. | |
With oxalyl dichloride; N,N-dimethyl-formamide; In dichloromethane; at 0 - 20℃; for 3h;Inert atmosphere; Schlenk technique; | General procedure: To a stirred solution of the fatty acid (1 eq., 0.78 mmol) and a dropof DMF in dry dichloromethane (5 ml) was added dropwise oxalylchloride (3 eq., 297 mg, 2.34 mmol) at 0 C. The reaction mixture waswarmed slowly up to rt and stirred for further 3 h. Solvent and excessoxalyl chloride were removed in vacuo and the resulting acid chloridewas used next step without purification. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
EXAMPLE 5 Tridecanedioic acid 338.58 g (1 mol) of erucic acid (purity 95%) were ozonized in analogy to Example 1 and then hydrogenation was carried out. The hydrogenation solution obtained in this way contained nonanal and tridecanealdehyde acid and was divided by distillation. For oxidation, the corresponding aldehyde fraction was employed and was oxidized at 14 bar in analogy to Example 1. 185 g of tridecanedioic acid per cycle were obtained with a purity of 95%. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
90.3% | With palladium 10% on activated carbon; hydrogen; In tetrahydrofuran; at 20 - 30℃; under 4500.45 - 6000.6 Torr; | 13-Docosenoic acid (100 g) was suspended in THF (1500 ml) at 20-30C and hydrogenated in the presence of Palladium on charcoal (5 g, 10% w/w, 50 % wet) at 20-30 C over a hydrogen pressure of 6-8 Kg/cm . After completion of reaction the catalyst was filtered off, solvent was evaporated from the filtrate under reduced pressure (20-40 mm Hg) at 40-50 C to get a white colour residue. The above residue was suspended in methanol (1000 ml) and heated to 60-65C to obtain a clear solution and cooled to 20-30C slowly over a period of 30+5 min stirred for an hour at 20-30 C. The resulting solid was filtered and dried under reduced pressure (10-20 mm Hg) at 40-45 C to afford 90.83 g of Docosanoic acid. Yield: 90.3 % of theory Chromatographic purity (by GC): >98 % |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
42% | With 2Zn(2+)*(CH3)3NC2H4OH(1+)*5Cl(1-)=[HOC2H4N(CH3)3]Zn2Cl5; at 150℃; for 4h; | (a) gamma-undecalactone: A mixture of 10-undecenylic acid (2.0 g; 10.8 mmol) and IL (2.23 g; 5.4 mmol) was stirred at 130 C. After 8 h, the product was separated from IL by extracting first with ethyl acetate then with hexane. The organic solvent was evaporated using rotary evaporator and dried under vacuum to get 1.88 g of peach flavored gamma-undecalactone as clear oil (isolated yield, 94%). The structure of the product was confirmed by 1H and 13C NMR, ESI-Mass and matched well with literature report.81H NMR (300 MHz, CDCl3, delta): 4.46 (tt, 1H, CH-O), 2.51 (dd, 2H, alpha-CH2), 2.31-2.26 (m, 1H, beta-CH2), 1.90-1.75 (m, 1H, beta-CH2), 1.75-1.60 (m, 1H, delta-CH2), 1.60-1.50 (m,1H, delta-CH2), 1.40-1.20 (m, 10H, 5CH2), 0.85 (t, 3H, CH3). 13C NMR (75 MHz, CDCl3, delta):14.0-29.5 (CH2), 31.8 (beta-CH2), 35.5 (alpha-CH2), 81.1 (CH-O), 177.1 (C=O). ESI-Mass m/z: [m++Na] 207, [m++1+Na] 208. (b) gamma-stearolactone: A mixture of oleic acid (2 g, 7.8 mmol) and IL (2.9 g, 7.8 mmol) was stirred at 150 C. After 4 h, the product was separated from IL by extracting first with a binary mixture of ethyl acetate and hexane (30:70) and finally with hexane. The organic solvent was evaporated to get 1.73 g of crude product, which was crystallized from acetone at -20 C to get 1.48 g of gamma-stearolactone as white solid (isolated yield, 74%). The structure of the product was confirmed by 1H and 13C NMR, ESI-Mass and matched well with literature report.41H NMR (300 MHz, CDCl3, delta): 4.46 (tt, 1H, CH-O), 2.51 (dd, 2H, alpha-CH2), 2.31-2.26(m, 1H, beta-CH2), 1.90-1.75 (m, 1H, beta-CH2), 1.75-1.60 (m, 1H, delta-CH2), 1.60-1.50 (m, 1H, delta-CH2), 1.40-1.10 (m, 24H, 12CH2), 0.85 (t, 3H, CH3). 13C NMR (75 MHz, CDCl3, delta):14.0-29.5 (CH2), 31.8 (beta-CH2), 35.5 (alpha-CH2), 81.1 (CH-O), 177.1 (CO). ESI-Mass m/z: [m++Na] 305.3, [m++1+Na] 306.3. (c) gamma-erucalactone: A mixture of erucic acid (2 g, 5.9 mmol) and IL (2.42 g, 5.9 mmol) was stirred at 150 C. After 4 h, the product was separated from IL by extracting first with ethyl acetate and then with hexane. The organic solvent was evaporated to get 1.86 g of crude product, which was crystallized from acetone at -20 C to get 0.8 g of gamma-erucalactone as white solid (isolated yield is 42%). The structure of the product was confirmed by 1H NMR, 13C NMR and ESI-Mass. 1H NMR (300 MHz, CDCl3, delta): 4.46 (tt, 1H, CH-O), 2.51 (dd, 2H, alpha-CH2), 2.31-2.26(m, 1H, beta-CH2), 1.90-1.75 (m, 1H, beta-CH2), 1.75-1.60 (m, 1H, delta-CH2), 1.60-1.50 (m,1H, delta-CH2), 1.40-1.10(m, 32H, 16CH2), 0.85 (t, 3H, CH3). 13C NMR (75 MHz, CDCl3, delta):14.0-29.5 (CH2), 31.8 (beta-CH2), 35.5 (alpha-CH2), 81.1 (CH-O), 177.1 (CO). ESI-Mass m/z: [m++Na] 361.4, [m++1+Na] 362.4. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In dichloromethane; at 0 - 20℃; for 16h; | General procedure: For reaction 1-To a solution of the desired free fatty acid (1.0equivalent) and 1,2-isopropylideneglycerol (1.0 equivalent) inanhydrous dichloromethane (CH 2 Cl 2 , 1.5 ml) maintained at0 C, N,N-dimethyl-4-aminopyridine (0.25 equivalent) andEDC HCl (1.0 equivalent) was sequentially added. The reactionmixture was warmed to room temperature and stirred for 16 h.Upon disappearance of starting compound observed on TLC,the reaction was quenched with saturated sodium bicarbonate(NaHCO 3 ) and extracted three times with CH 2 Cl 2 . The combinedorganic layer was dried over sodium sulfate (Na 2 SO 4 ) and filtered,and the filtrate was concentrated. The crude residue was purifiedby column chromatography using 5% ethyl acetate/hexane as aneluent to afford the corresponding fatty acid ester. For reaction 2-Amberlyst-15 (Hform, 0.5 equivalent) wasadded to a solution of fatty acid ester (1.0 equivalent) in MeOH.The resulting reaction mixture was stirred for 16 h at roomtemperature. After completion of reaction (TLC analysis),Amberlyst-15 was filtered off, and the filtrate was evaporatedunder reduced pressure. The crude residue was purified by col-umn chromatography using 40% ethyl acetate/hexane as an elu-ent to afford the corresponding 1-MAG lipid. The detailed syn-thesis and compound characterization data of each individual1-MAG lipid can be found in the supporting information. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
70% | Synthesis of 1,26-hexacos-13-enedioic acid (5d): Diacid 5d was synthesized from 3d as above. The pure diacid was obtained by recrystallization from acetone in a yield of 70%, m.p.=105-107.5 C. (lit. m.p.=96 C. (Van Dam, P. B., et al., J. Am. Oil. Chem. Soc., 51: 389-391 (1974)). 1H NMR (CD3OD, 200 MHz): delta 5.4 (m, CHCH, 2H), 2.28 (t, J=7.4 Hz & 7.4 Hz, CH2CO2H, 4H), 1.97 (m, CH2CHCH, 4H), 1.6 (m, 4H), 1.30 (m, 32H). 13C NMR (CD3OD, 50 MHz): delta 177.9 (s, -CO2H), 131.7 (s, -CHCH-), 35.2 (s), 33.7 (s), 30.9 (s), 30.8 (s), 30.78 (s), 30.7 (s), 30.6 (s), 30.4 (s), 30.3 (s), 26.3 (s). The methyl ester of diacid 5d was analyzed by GC/MS (retention time t=28.2 min) and had an [M]+ of m/z 452 (calc., [M]+ m/z 452.38). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
93% | With choline chloride; zinc(II) chloride at 110℃; for 12h; |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Multi-step reaction with 6 steps 1: 91 percent / 30percent H2O2, HCOOH 2: 89 percent / aq. Na2CO3, H3PO4, NaIO4 3: 1.) NaH, DMSO 4: PTS 5: 90 percent / LiAlH4 (LAH) / diethyl ether 6: 100 percent / pyridine / 24 h / Ambient temperature |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
100% | In methanol; at 30 - 60℃; for 1 - 2h; | EXAMPLE 7; - Preparation of fatty derivative salts from pure quaternary hydroxide (denatonium eruciate); 50 grams (0.1462 mol) of denatonium hydroxide was dissolved in 50 ml of methanol at 30-45 C. A solution of 54.5 gram (0.1462 mol i.e. 1 mole erucic acid against 1 mol denatonium hydroxide) of erucic acid (with 90.7 % assay) in 50 ml of methanol was added at 30-45 C, and the thus obtained mixture was stirred for 1 - 2 hours at 45-60 C temperature. The solvent was then distilled off up to yellow thick semi solid mass. 101 grams of denatonium eruciate was obtained with a quantitative yield. (Assay = 99.09%, S' Ash = 0.08%). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
82% | With sulfuric acid; In toluene; | EXAMPLE VI Five-hundred grams molten erucic acid were slowly added to a mixture of 679 gms toluene and 723 gms concentrated sulfuric acid while maintaining the temperature below 10 C. Tolyldocosanoic acid (acid value 123) was obtained in 82% yield. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With potassium hydroxide; at 160℃; for 12h;Inert atmosphere; | erucic acid, purity 90% (W),Bellingham Technology Co., Ltd.; N, N-dimethylaminopropylamine,N, N-ethylaminopropylamine, purity 90% (W),Shanghai Jing Chun Biochemical Technology Co. 3-bromo-1-propanol, purity 95% (W)Shaoyuan (Shanghai) Chemical Technology Co.Potassium hydroxide, analytical grade, Sinopharm Group Chemical Reagent Co.Nicolet 6700 Fourier transform infrared spectrometer,Thermo Fisher Scientific;RS6000 Huck Rotational Rheometer,Quadruple LC / MS 6120 LC / MS,Agilent Technologies.Comprising the steps of: (1) Erucic acid was added to a three-neck flask equipped with a reflux condenser and a stirrerN, N-dimethylaminopropylamine (or N, N-ethylaminopropylamine), (2) under argon(3) After completion of the reaction, unreacted N, N-dimethylaminopropylamine (or N, N-ethylaminopropylamine) was removed by rotary evaporation.The product erucic amide propyl dimethyl (ethyl) amine. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
gel-type acidic ion exchange resin; In canola oil; at 60 - 67℃; under 760.051 Torr;Molecular sieve; | Example 1: Selective Esterification; Comparing fatty acids with differing chain lengths; In a four-neck 1L RB flask equipped with a Soxhlet condenser containing 50 g activated molecular sieves 3A, thermometer and mechanical stirrer, was added dry polymeric catalyst (13.75 g, 5% by weight of reaction mixture). Canola oil (202.5 g, 0.23 moles triglycerides) was charged to the flask and mechanical stirring started at 185 RPM. Then, erucic acid (37.9g, 0.112 moles) and lauric acid (22.4 g, 0.112 moles) were added and the flask was heated by external infrared lamp to reach 60 C over 20 minutes. At 60 C, methanol (4 g, 0.13 mole or 1.1 equivalent of lauric acid) was charged to the flask. The mixture was allowed to reach reflux temperature (?65-67C) with efficient stirring (235 rpm). The reflux was condensed through a water condenser and passed through the molecular sieves back into the flask. The reaction was carried out at 65C-67C (reflux temperature) and atmospheric pressure for 30 min. After 30 min., the mixture was cooled to ambient temperature. The catalyst was recovered by filtration from the organic phase. Conversion of specific acids is summarized in Table 1 |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
General procedure: All fatty acid amides with different acyl chains and amine heads were synthesized using the same procedure but with different precursor compounds. 2-(1H-Benzotriazole-1-yl)-1,2,3,3-tetramethyluronium tetrafluoroborate (TBTU, 1 equiv) was added to a mixture of compound C1 (1 equiv) and triethylamine (TEA, 2 equiv) in EtOAc. After stirring for 1 h at room temperature, isopropylamine (2 equiv) was added and the reaction mixture was stirred for 12 h. The mixture was washed with water, dried and concentrated to give a residue that was purified by reversed-phase HPLC (YMC ODS-H80) eluting with 80% aqueous CH3CN to yield compound 1 (1.5 mg, 63%); |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
General procedure: All fatty acid amides with different acyl chains and amine heads were synthesized using the same procedure but with different precursor compounds. 2-(1H-Benzotriazole-1-yl)-1,2,3,3-tetramethyluronium tetrafluoroborate (TBTU, 1 equiv) was added to a mixture of compound C1 (1 equiv) and triethylamine (TEA, 2 equiv) in EtOAc. After stirring for 1 h at room temperature, isopropylamine (2 equiv) was added and the reaction mixture was stirred for 12 h. The mixture was washed with water, dried and concentrated to give a residue that was purified by reversed-phase HPLC (YMC ODS-H80) eluting with 80% aqueous CH3CN to yield compound 1 (1.5 mg, 63%); |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
General procedure: All fatty acid amides with different acyl chains and amine heads were synthesized using the same procedure but with different precursor compounds. 2-(1H-Benzotriazole-1-yl)-1,2,3,3-tetramethyluronium tetrafluoroborate (TBTU, 1 equiv) was added to a mixture of compound C1 (1 equiv) and triethylamine (TEA, 2 equiv) in EtOAc. After stirring for 1 h at room temperature, isopropylamine (2 equiv) was added and the reaction mixture was stirred for 12 h. The mixture was washed with water, dried and concentrated to give a residue that was purified by reversed-phase HPLC (YMC ODS-H80) eluting with 80% aqueous CH3CN to yield compound 1 (1.5 mg, 63%); |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
General procedure: All fatty acid amides with different acyl chains and amine heads were synthesized using the same procedure but with different precursor compounds. 2-(1H-Benzotriazole-1-yl)-1,2,3,3-tetramethyluronium tetrafluoroborate (TBTU, 1 equiv) was added to a mixture of compound C1 (1 equiv) and triethylamine (TEA, 2 equiv) in EtOAc. After stirring for 1 h at room temperature, isopropylamine (2 equiv) was added and the reaction mixture was stirred for 12 h. The mixture was washed with water, dried and concentrated to give a residue that was purified by reversed-phase HPLC (YMC ODS-H80) eluting with 80% aqueous CH3CN to yield compound 1 (1.5 mg, 63%); |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
General procedure: All fatty acid amides with different acyl chains and amine heads were synthesized using the same procedure but with different precursor compounds. 2-(1H-Benzotriazole-1-yl)-1,2,3,3-tetramethyluronium tetrafluoroborate (TBTU, 1 equiv) was added to a mixture of compound C1 (1 equiv) and triethylamine (TEA, 2 equiv) in EtOAc. After stirring for 1 h at room temperature, isopropylamine (2 equiv) was added and the reaction mixture was stirred for 12 h. The mixture was washed with water, dried and concentrated to give a residue that was purified by reversed-phase HPLC (YMC ODS-H80) eluting with 80% aqueous CH3CN to yield compound 1 (1.5 mg, 63%); |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
General procedure: All fatty acid amides with different acyl chains and amine heads were synthesized using the same procedure but with different precursor compounds. 2-(1H-Benzotriazole-1-yl)-1,2,3,3-tetramethyluronium tetrafluoroborate (TBTU, 1 equiv) was added to a mixture of compound C1 (1 equiv) and triethylamine (TEA, 2 equiv) in EtOAc. After stirring for 1 h at room temperature, isopropylamine (2 equiv) was added and the reaction mixture was stirred for 12 h. The mixture was washed with water, dried and concentrated to give a residue that was purified by reversed-phase HPLC (YMC ODS-H80) eluting with 80% aqueous CH3CN to yield compound 1 (1.5 mg, 63%); |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
General procedure: All fatty acid amides with different acyl chains and amine heads were synthesized using the same procedure but with different precursor compounds. 2-(1H-Benzotriazole-1-yl)-1,2,3,3-tetramethyluronium tetrafluoroborate (TBTU, 1 equiv) was added to a mixture of compound C1 (1 equiv) and triethylamine (TEA, 2 equiv) in EtOAc. After stirring for 1 h at room temperature, isopropylamine (2 equiv) was added and the reaction mixture was stirred for 12 h. The mixture was washed with water, dried and concentrated to give a residue that was purified by reversed-phase HPLC (YMC ODS-H80) eluting with 80% aqueous CH3CN to yield compound 1 (1.5 mg, 63%); |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
98.8% | With ammonia; zircornium(IV) n-propoxide; at 165℃; for 6.0h; | General procedure: According to the embodiment of the present invention described above, stearic acid amide, which is a kind of carboxylic acid amide compound, was prepared in Example 1 as follows. First, the carboxylic acid injector 250 injects 1000 g of stearic acid into the heater 100, and the heater 100 heats 1000 g of stearic acid to 120 C. Subsequently, when stearic acid is injected into the first reaction tank 210, the first catalyst injector 261 injects 10 g of tetraisopropyl titanium, which is a metal catalyst, into the first reaction tank 210, Was heated by the heater attached to the first reaction tank 210. When 150 g of stearic acid was charged into the first reaction tank 210, the first ammonia injector 281 started to feed the ammonia gas through the ammonia pipe 283 at a rate of 100 L / hr. When 500 g of stearic acid was charged into the first reaction tank 210, the introduction of stearic acid into the first reaction tank 210 was stopped. The propeller in the first reaction tank 210 was mixed with stearic acid and ammonia while maintaining the reaction temperature at 165 C in the first reaction tank 210.Next, when the supply of the stearic acid to the first reaction tank 210 is stopped, the 500 g of stearic acid remaining in the heater 100 through the valve is changed to be supplied to the second reaction tank 220. When stearic acid is injected into the second reaction tank 220, the second catalyst injector 262 injects 10 g of tetraisopropyl titanium as a metal catalyst into the second reaction tank 220 and starts heating the second reaction tank 220 . When 150 g of stearic acid was charged into the second reaction tank 220, the second ammonia feeder 282 started to feed the ammonia gas through the ammonia pipe 283 at a rate of 100 L / hr. When all 500 g of stearic acid was fed to the second reaction tank, the addition of stearic acid to the second reaction tank was stopped. The propeller in the second reaction tank 220 was mixed with stearic acid and ammonia while maintaining the reaction temperature of 165 C in the second reaction tank 220.In Examples 2 to 10, other carboxylic acid amide compounds were prepared in the same manner as in Example 1, except that stearic acid was used instead of stearic acid and other carboxylic acids as shown in the following Table 1 as "acid". |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
91.8% | With dmap; dicyclohexyl-carbodiimide; In chloroform; at 20℃;Cooling with ice; | Procedure 1: To a solution of fatty alcohol (typically 1-100 mmol, preferably 5- 50 mmol, and most preferably, 10 mmol) in Chloroform (typically 1-100 mL, preferably 10-50 mL, and most preferably, 20 mL), fatty acid (typically 1-100 mmol, preferably 5- 50 mmol, and most preferably 10.1 mmol), 4-dimethylaminopyridine (typically 1-100 mmol, preferably 5-50 mmol, and most preferably 10 mmol) was added. To this reaction mixture in an ice bath, dicyclohexyl-carbodiimide (typically 1-100 mmol, preferably 5-50 mmol, and most preferably 11 mmol) in Chloroform was added slowly and the reaction was stirred at a temperature (typically between 4-50 C, preferably between 12-33 C, and most preferably between 17-27 C) overnight. The precipitated dicyclohexylurea was removed by filtration. The organic phase was then washed sequentially with water, 5%HCI, 4% NaHC03, water. The solvents were roto-evaporated and the residue was purified by column chromatography with Ethyl Acetate/ Hexane to give a colorless oil.; Docos-13-enoic acid octadec-9-enyl ester (Compound B)Compound B was prepared from Erucic acid and Oleyl alcohol in the presence of DCC and DMAP following the general procedure discussed before and as shown in Figure 7. Pure compound B was a colorless oil obtained by column chromatography with Ethyl acetate/ Hexane= 1 :40. Reaction conditions for branched derivative compounds B2, B3, and B4 are also shown below.Yield: 91.8%1 H-NMR in CDCI3 (ppm), 5.4 (4, m), 4.1 (2, t), 2.3 (2, t), 2.1-2.0 (8, m), 1.7-1.56 (4, m), 1.44-1.20 (50, m), 0.86-0.76 (6, t)Purity: >95% |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With toluene-4-sulfonic acid In toluene at 120℃; Dean-Stark; |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With toluene-4-sulfonic acid In toluene at 120℃; Dean-Stark; |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
96% | With Zn-MCM-22 catalyst; at 80 - 340℃; under 15001.5 Torr; for 6h;Inert atmosphere; Large scale; | In a 2-cubic stirred reactor, 507 kg of erucic acid, 1095 kg of diethylamine was added,Heated to 80 C, open stirring, and keep the stirring speed of 120 r / min, until the benzoic acid in diethylamine completely dissolved, pointsNo free benzoic acid raw materials in the raw materials.The reactor is filled with Zn-MCM-22 catalyst with an effective volume of about 2 m3, about 1.6 tons of catalyst, and the reactor is chargedAfter full nitrogen, open the circulating compressor, nitrogen circulation of 8m3 / min. Through the reactor upper pressure regulating valve, the reactorThe pressure was maintained at 2.0 MPa and the temperature of the reactor catalyst bed was slowly raised to 300 C by means of a heat exchanger. Start the feed pump to250 kg / h of liquid flow rate of raw materials into the raw material preheater, the material heated to 340 , through the heat exchanger reactor gasPhase discharge temperature dropped to 150 C into the gas-liquid separator, in the separator, most of the water as the liquid phase in the bottom of the separatorDeposition, the gas phase for the circulating nitrogen and a small amount of organic amine raw materials, after heating and boosting, re-entering the reaction from the bottom of the reactorWhich is countercurrently contacted with the reaction product to provide the heat required for the reaction and to continuously remove the moisture from the organic ammonium salt from the reactorTo promote the progress of the reaction. |
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In dichloromethane; at 20℃; for 24h; | (1) Weigh 16.92g (0.05mol)Cis-docosa-13-enoic acid(common name "erucic acid") dissolved in methylene chloride,4.02 g (0.055 mol) of diethylamine was added in sequence,19.1 g (0.1 mol) of EDC·HCl,After the dissolution was completed, 1.22 g (0.01 mol) of DMAP was further added, and the mixture was reacted at room temperature for 24 hours.After the reaction,The reaction solution was diluted with 250 mL of dichloromethane, followed by 0.1% HCl solution,The saturated NaHCO3 solution and the saturated NaCl solution were separately washed three times, and the organic phase was collected.It was dried over anhydrous MgSO4 for 2 h, filtered, and then evaporated and evaporated.Vacuum drying,That is, N,N-diethyl-N-n-docosylamide is obtained, and its structural characterization is shown in the 1H NMR spectrum (Fig. 1).The chemical shift of each proton peak in the compound has been found in the spectrum, and the integral area ratio of each proton resonance peak is in good agreement with the theoretical value.This indicates that the compound has been successfully synthesized. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In water; acetonitrile at 37℃; for 2.5h; |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
62% | With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In dichloromethane; at 20℃; for 2h; | General procedure: A mixture of sinomenine hydrochloride (1 mmol), Sorbic acid (1.5 eq), EDC(1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 2.0 eq), DMAP(4-dimethylaminopyridine) in CH2Cl2, was stirred at room temperature for 2 h, followedby addition of water, the solution was extracted with CH2Cl2. The combined extract wasdried with anhydrous NaSO4. The residue was separated by column chromatography togive the pure sample. Oily substance; yield 70%. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
73% | With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In dichloromethane; at 20℃; for 2h; | General procedure: A mixture of sinomenine hydrochloride (1 mmol), Sorbic acid (1.5 eq), EDC(1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 2.0 eq), DMAP(4-dimethylaminopyridine) in CH2Cl2, was stirred at room temperature for 2 h, followedby addition of water, the solution was extracted with CH2Cl2. The combined extract wasdried with anhydrous NaSO4. The residue was separated by column chromatography togive the pure sample. Oily substance; yield 70%. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
61% | With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In dichloromethane; at 20℃; for 2h; | General procedure: A mixture of sinomenine hydrochloride (1 mmol), Sorbic acid (1.5 eq), EDC(1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 2.0 eq), DMAP(4-dimethylaminopyridine) in CH2Cl2, was stirred at room temperature for 2 h, followedby addition of water, the solution was extracted with CH2Cl2. The combined extract wasdried with anhydrous NaSO4. The residue was separated by column chromatography togive the pure sample. Oily substance; yield 70%. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
61% | With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In dichloromethane; at 20℃; for 2h; | General procedure: A mixture of sinomenine hydrochloride (1 mmol), Sorbic acid (1.5 eq), EDC(1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 2.0 eq), DMAP(4-dimethylaminopyridine) in CH2Cl2, was stirred at room temperature for 2 h, followedby addition of water, the solution was extracted with CH2Cl2. The combined extract wasdried with anhydrous NaSO4. The residue was separated by column chromatography togive the pure sample. Oily substance; yield 70%. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
83% | Add erucic acid 7 to a single-necked flask and dissolve it in dichloromethane with stirring. HBTU (1.05eq) and DIEA (2eq) were added. After the addition was complete, the mixture was stirred at room temperature for 2h. Diethanolamine (2eq) was added. After the addition was complete, stir at room temperature for 18h. The reaction solution was washed with water and dilute hydrochloric acid, and then dried over anhydrous sodium sulfate. Filter and concentrate the filtrate to dryness to give a crude product. The crude product was passed through a silica gel column to obtain compound 8 with a yield of about 83 % |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
54% | With (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate; triethylamine; In dichloromethane; at 22 - 23℃; for 2h; | General procedure: To a suspension of CP (0.20g; 0.60mmol) and an appropriate fatty acid (0.60mmol) in dried CH2Cl2 (24ml), the BOP reagent (benzotriazol-1-yloxy)tris(dimethylamino) phosphonium hexafluorophosphate) (0.27g, 0.60mmol) and triethylamine (0.13mL; 0.91mmol) were added. The resulting solution was stirred for 2hat 22-23C. To the obtained reaction mixture, 0.67% HClaq solution (15mL) was added. Next, it was extracted with CH2Cl2 (2×25 mL). The combined organic layers were washed with 1% HClaq solution (4×25 mL) and distilled water (2×25 mL), and then dried over anhydrous MgSO4. After the solvent evaporation, the product was isolated using column chromatography on silica gel (with CH2Cl2:MeOH mixture as an eluent). The final product was washed with diethyl ether (2×2 mL). The structures of all compounds were confirmed by 1H NMR, 13C NMR and MS spectra (see Supplementary material). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With sphingolipid ceramide N-deacylase; In aq. acetate buffer; at 37℃; for 1.5h;pH 5.5;Enzymatic reaction; | General procedure: Individual Gb3 molecules were synthesized by the reverse reaction of SCDase with purified lyso-Gb3 or its analogs and purchased fatty acids. The preparations LG3, LG3(-2), and LG3(+18) described in Fig. 3 were used as purified lyso-Gb3, lyso-Gb3(-2), and lyso-Gb3(+18), respectively. For example, when a Gb3 isoform Gb3(d18:1)(C18:0) was synthesized, LG3 and stearic acid was used. Approximately 0.5 mug of LG3 was mixed with 25mug of stearic acid dissolved in CHCl3/MeOH (2:1 (v/v)) and dried. Lipids were suspended in 40 mul of enzyme mixture (5 mug/ml of SCDase in 25 mM sodium acetate buffer (pH 5.5) containing 0.5% Triton X-100, 5 mM CaCl2, and 5% DMSO) and incubated at 37 C for 1.5 h. The reaction was stopped by the addition of 0.8 ml of CHCl3/MeOH (2:1 (v/v)), and aqueous lipids were separated by the addition of 0.2 ml of 1.5% FA in H2O and centrifugation at 6500xg for 5 min. After removal of the upper layer, the product was recovered in the lower layer and designated as LG3/C18:0. In a manner similar to Gb3 isoforms, when Gb3 analogs Gb3(-2) and Gb3(+18) containing stearic acid were synthesized, LG3(-2) and LG3(+18) were used, respectively. All synthesized Gb3 standards were adjusted to concentrations at 3,000 peak area when determined by UPLC-MS/MS. In the direct assay, Gb3(d18:2)(C17:0) was used as an internal standard, which was synthesized enzymatically from LG3(-2) and heptadecanoic acid by the same method as described above. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With sphingolipid ceramide N-deacylase; In aq. acetate buffer; at 37℃; for 1.5h;pH 5.5;Enzymatic reaction; | General procedure: Individual Gb3 molecules were synthesized by the reverse reaction of SCDase with purified lyso-Gb3 or its analogs and purchased fatty acids. The preparations LG3, LG3(-2), and LG3(+18) described in Fig. 3 were used as purified lyso-Gb3, lyso-Gb3(-2), and lyso-Gb3(+18), respectively. For example, when a Gb3 isoform Gb3(d18:1)(C18:0) was synthesized, LG3 and stearic acid was used. Approximately 0.5 mug of LG3 was mixed with 25mug of stearic acid dissolved in CHCl3/MeOH (2:1 (v/v)) and dried. Lipids were suspended in 40 mul of enzyme mixture (5 mug/ml of SCDase in 25 mM sodium acetate buffer (pH 5.5) containing 0.5% Triton X-100, 5 mM CaCl2, and 5% DMSO) and incubated at 37 C for 1.5 h. The reaction was stopped by the addition of 0.8 ml of CHCl3/MeOH (2:1 (v/v)), and aqueous lipids were separated by the addition of 0.2 ml of 1.5% FA in H2O and centrifugation at 6500xg for 5 min. After removal of the upper layer, the product was recovered in the lower layer and designated as LG3/C18:0. In a manner similar to Gb3 isoforms, when Gb3 analogs Gb3(-2) and Gb3(+18) containing stearic acid were synthesized, LG3(-2) and LG3(+18) were used, respectively. All synthesized Gb3 standards were adjusted to concentrations at 3,000 peak area when determined by UPLC-MS/MS. In the direct assay, Gb3(d18:2)(C17:0) was used as an internal standard, which was synthesized enzymatically from LG3(-2) and heptadecanoic acid by the same method as described above. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
94% | With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine; In dichloromethane; at 20℃; for 18h;Inert atmosphere; | General procedure: To a stirring solution of 4-bromopiperidinium hydrobromide bromide (1.0 equiv), EDC (1.5 equiv) andDMAP (10 mol %) in anhydrous CH2Cl2 (0.50 M) under an atmosphere of nitrogen was added N,Ndiisopropylethylamine(2.0 equiv). The corresponding carboxylic acid (1.0-1.1 equiv) in CH2Cl2 (to 2.0M of limiting reagent) was added dropwise to the above solution over 5 minutes. The mixture wasstirred at room temperature for 18 h. Then, the mixture was concentrated in vacuo and suspended inaqueous 1 M NaOH (5.0 mL/mmol) and extracted with EtOAc (3 × 5.0 mL/mmol). The organicextracts were combined and washed with 1 M HCl (5.0 mL/mmol), brine (5.0 mL/mmol), dried overNa2SO4 and concentrated in vacuo. The residue was purified by column chromatography under theconditions noted to yield the desired product. |
Tags: 112-86-7 synthesis path| 112-86-7 SDS| 112-86-7 COA| 112-86-7 purity| 112-86-7 application| 112-86-7 NMR| 112-86-7 COA| 112-86-7 structure
[ 1614-73-9 ]
Cyclohept-4-enecarboxylic acid
Similarity: 0.84
[ 2305-26-2 ]
(1R,2S)-rel-Cyclohex-4-ene-1,2-dicarboxylic acid
Similarity: 0.81
[ 5708-19-0 ]
(S)-Cyclohex-3-enecarboxylic acid
Similarity: 0.81
[ 1614-73-9 ]
Cyclohept-4-enecarboxylic acid
Similarity: 0.84
[ 2305-26-2 ]
(1R,2S)-rel-Cyclohex-4-ene-1,2-dicarboxylic acid
Similarity: 0.81
[ 5708-19-0 ]
(S)-Cyclohex-3-enecarboxylic acid
Similarity: 0.81
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :